Role of Amisulpride and Granisetron for prevention of postoperative nausea and vomiting after high risk surgery undergoing general anesthesia.

Comparative study between Amisulpride and Granisetron for prevention of postoperative nausea and vomiting in patient undergoing general Anaesthesia: A Rndomized Controlled double blind Study. - nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/06/069635

Enrollment

Registered

2024-06-27

Start date

Unknown

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: nil: nil Intervention2: Injection Amisulpride 5mg/2ml: Amisulpride 5mg/2ml (Trade name Sultaren manufactured by La Renon ltd, India.) with 8mg dexamethasone. Dose- 5mg as a single intra

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients willing to participate. 2.Patients 18-70 years of age of either gender. 3.ASA grade 1-3 patients. 4.Operative procedure requiring General Anaesthesia.

Exclusion criteria

Exclusion criteria: Any contraindications to General Anaesthesia. 1.Patients with history of motion sickness. 2.Patients with pregnancy. 3.Lactating Mother. 4.Patients on chronic anti emetic medications.

Design outcomes

Primary

Measure	Time frame
To evaluate the incidence of PONV in patients undergoing General anesthesia.Timepoint: Time interval 0-6 hr,6-12 hr,12-24hr	—

Secondary

Measure	Time frame
To assess the secondary efficacy variables i.e. 1.Post operative need of anti-emetics. 2.Adverse effects, if any. Timepoint: 1 year	—

Countries

India

Contacts

Public ContactJay prakash ravi

IGIMS patna

drbibha98aditi@gmail.com8252410069

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026